Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 13/20 | 0.69 |
| ▸ | EGFR | P00533 | 13/20 | 0.69 |
| ▸ | STK4 | Q13043 | 6/20 | 0.69 |
| ▸ | STK3 | Q13188 | 5/20 | 0.69 |
| ▸ | SRC | P12931 | 2/20 | 0.69 |
| ▸ | KDR | P35968 | 2/20 | 0.69 |
| ▸ | STK25 | O00506 | 1/20 | 0.69 |
| ▸ | MAP2K7 | O14733 | 1/20 | 0.69 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.69 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.69 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.69 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.69 |
| ▸ | STK17B | O94768 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.69 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10054545 | 0.93 | EGFR (0.79) | ERBB2EGFRSTK4STK3SRC | |
| SCHEMBL14765641 | 0.92 | ERBB2 (0.67) | ERBB2EGFRSTK4STK3SRC | |
| SCHEMBL9883172 | 0.88 | ERBB2 (0.87) | ERBB2EGFRSTK4STK3SRC | |
| SCHEMBL10023955 | 0.88 | EGFR (0.73) | ERBB2EGFRSTK4STK3SRC | |
| SCHEMBL2129397 | 0.84 | EGFR (0.84) | ERBB2EGFRSTK4STK3SRC | |
| SCHEMBL24037452 | 0.83 | ERBB2 (0.89) | ERBB2EGFRSTK4STK3SRC | |
| SCHEMBL2130964 | 0.81 | ERBB2 (0.86) | ERBB2EGFRSTK4STK3SRC | |
| Neratinib SCHEMBL571763 | 0.81 | ERBB2 (1.00) | ERBB2EGFRSTK4STK3SRC | |
| Neratinib SCHEMBL15163655 | 0.81 | ERBB2 (1.00) | ERBB2EGFRSTK4STK3SRC | |
| Neratinib SCHEMBL571762 | 0.81 | ERBB2 (1.00) | ERBB2EGFRSTK4STK3SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289545-A1 | Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof | LU QINGHONG (US) | 2012-11-15 | — | — | US | disclosed |
| US-8173814-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2012-05-08 | — | — | US | disclosed |
| US-8022216-B2 | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof | WYETH LLC (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090176827-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | WYETH (US) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289545-A1 | Maleate Salts of (E)-N--4-(Dimethylamino)-2-Butenamide and Crystalline Forms Thereof | EGFR, ERBB4, ALK | ERBB2 4/4885EGFR 1/4885STK4 251/4885 |
| US-20090176827-A1 | MALEATE SALTS OF (E)-N--4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF | EGFR, ERBB4, ALK | ERBB2 4/4885EGFR 1/4885STK4 251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.